This user has not added any information to their profile yet.
I am representing BrainXell (www.brainxell.com ). It offers human stem cell-based products and services in drug discovery for neurological and psychiatric diseases. Core technologies were developed in the lab of Steenbock Professor Su-Chun Zhang at the University of Wisconsin (UW)-Madison. He is a pioneer in neural stem cell and one of the founders of the company. The technologies are further optimized at BrainXell to direct human iPSCs to subtype-specific neuronal progenitors for expansion followed by rapid maturation. This reliable approach allows for large-scale production of highly enriched functional neurons with consistent quality for drug discovery and cell therapy. We have dual business model leveraging our common technological assets. While our neural cell products and services in preclinical market have been growing nicely to be profitable, we are raising fund to adapt our cell production technologies to a cGMP environment. We will produce large numbers of high-purity neural cells efficiently that could be used for Parkinson’s disease (PD) and multiple sclerosis (MS)/spinal cord injury (SCI).